Halloran Continues Growth Trend, Broadening its Client Offerings and Strategic Expertise

- Addition of Emily Walsh, Ph.D. and Melissa Clark Strengthens Alliance Management, Translational Program Management, and Regulatory Strategy Capabilities -

BOSTON--(BUSINESS WIRE)-- Halloran Consulting Group (Halloran), today announced the addition of Emily Walsh, Ph.D. as a Principal Consultant and Melissa Clark as a Senior Consultant. These are the latest in a recent series of staff additions that have substantially increased Halloran’s alliance management, translational program management, and regulatory strategy offerings.

Life sciences companies are optimizing product development through alliances, partnerships, and virtual organizational models at an ever-increasing rate. Given the industry’s increasing appetite for expertise in navigating these tricky areas, as well as the shifting regulatory environment, Halloran is continuing to expand its team.

“We are thrilled to add Emily and Melissa to our team, as both bring strong industry experience,” said Laurie Halloran, President of Halloran. “We are deeply committed to our clients and we believe our continued growth is a reflection of the industry’s appetite for experienced external guidance. As both the regulatory and funding environments have changed we have strategically positioned our growth to respond to those changes.”

Emily Walsh has broad expertise managing drug discovery and clinical programs across a breadth of indications, most recently as the CEO and founder of Tremont Therapeutics, a virtual biotech focused on identifying and developing promising therapeutics from academia, taking them from mid-discovery through human proof of concept. Prior to her work at Tremont, Emily was responsible for business, financial, alliance, and scientific program management across a number of research and development programs at Alnylam Pharmaceuticals, including the flagship respiratory syncytial virus therapeutics program. Emily also held various leadership roles at the Novartis Drug Discovery Incubator at the Novartis Institutes for Biomedical Research. This group sought to internally “partner” high-risk discovery programs within Novartis. She earned a Ph.D. from University of California, San Francisco, performed her postdoctoral work at the Broad Institute, and received her PMP certification in 2007.

Prior to joining Halloran, Melissa led the corporate regulatory affairs department at Boston Scientific where she provided regulatory strategic direction to highly technical, major business initiatives, and compliance programs. She also provided comprehensive global regulatory consult to corporate and divisional functions on medical device laws and regulations. Melissa has also held management positions at Interventional Therapies and Vivatone Hearing Systems where she led all aspects of clinical and regulatory affairs, resulting in marketing approval in the US and internationally. Prior to this, Melissa worked in regulatory and clinical affairs at US Surgical Corporation. Melissa is RAC certified. She holds a M.S. in Human Nutrition from the University of Bridgeport and a B.S. in Biology from Eastern Connecticut State University.

About Halloran Consulting Group

Halloran is a life sciences consulting firm specializing in enhancing the development process for biopharmaceutical and medical device companies. Our vision is to re-define product development processes in order to streamline required time and resources to achieve client business goals.

For more information, visit www.hallorancg.com.



CONTACT:

Corporate:
Halloran Consulting Group
Linda Hellstrom, 781-209-5440
[email protected]
or
Media:
MacDougall Biomedical Communications
Cory Tromblee, 781-235-3060
[email protected].com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical  Research  Science

MEDIA: